The authors suggested that their findings, when compared to previous, negative outcomes with CRF1 antagonists, support the idea that targeting the CRF/CRF1 signaling pathway may only be beneficial in a subset of patients who also display stress sensitivity, anxiety, and hyper-responsiveness of the HPA axis. The gene discussed is CRH; the disease is Anxiety.